Pipendoxifene hydrochloride is primarily used in research and development within the pharmaceutical industry. It is studied for its potential as a selective estrogen receptor modulator (SERM), which makes it a candidate for treating conditions related to estrogen imbalance. Its applications include investigating its efficacy in managing breast cancer, particularly in hormone receptor-positive cases, where it may help inhibit the growth of cancer cells. Additionally, it is explored for its potential in addressing osteoporosis by promoting bone density. Research also focuses on its role in menopausal symptom management, offering a possible alternative to traditional hormone replacement therapies. Its development continues to provide insights into targeted estrogen receptor therapies.